FDA Grants Accelerated Approval to Nuvalent’s Nelkarmi for Lung Cancer

The FDA granted accelerated approval to Nuvalent’s Nelkarmi (neladalkib) for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer. The approval covers patients who received either alectinib as their only prior ALK tyrosine kinase inhibitor or at least two prior ALK inhibitors and platinum-based chemotherapy in the unresectable locally advanced or metastatic setting.

The FDA evaluated efficacy using data from ALKOVE-1, a multicenter, open-label, single-arm trial. The main efficacy measures were confirmed overall response rate and duration of response, both assessed by blinded independent central review.

Among 67 patients who had received alectinib as their only prior ALK inhibitor, the overall response rate was 49%; among those who responded, 76% had responses lasting at least six months and 52% had responses lasting at least 12 months. Among 155 patients previously treated with at least two ALK inhibitors and platinum-based chemotherapy, the response rate was 32%; of those who responded, 69% had responses lasting at least six months and 51% had responses lasting at least 12 months.

The prescribing information includes warnings for liver, kidney and eye toxicity, elevated creatine phosphokinase and embryo-fetal toxicity. The most common adverse reactions included liver toxicity, musculoskeletal pain, constipation, altered taste, peripheral neuropathy, edema and fatigue.

The recommended dose is 150 mg by mouth once daily, with or without food, until disease progression or unacceptable toxicity. The application received priority review, and the drug received breakthrough therapy and orphan drug designations.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion